Session

Basic research in renal tumours: Gene profiling and molecular markers

Poster Session 18

  • Location:
    Room 14c (ICM, Level 1)
  • Chairs:
     L. Mengual, Barcelona (ES)
     A. Vuksanovic, Belgrade (RS)
  • Aims and objectives of this session

    To show and discuss latest advances in gene profiling as well as molecular markers of prognosis.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
217
Identifying the metastatic subclone by exhaustive sampling of primary and metastasis in clear cell renal cell carcinoma (ccRCC) pair

By: Soultati A.1, O’Brien T.2, Challacombe B.J.2, Nicol D.3, Horswell S.4, Xu H.5, Rowan A.J.5, Lopez J.I.6, Stares M.5, Chandra A.7, Chowdhury S.8, Rudman S.8, Matthews N.9, Larkin J.10, Turajlic S.5, Swanton C.5

Institutes: 1Guy’s and St’ Thomas NHS Foundation Trust, Dept. of Oncology, London, United Kingdom, 2Guy’s and St’ Thomas NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 3Royal Marsden Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 4The Francis Crick Institute, Dept. of Bioinformatics and Biostatistics, London, United Kingdom, 5The Francis Crick Institute, Translational Cancer Therapeutics Laboratory, London, United Kingdom, 6Cruces University Hospital, Dept. of Pathology, Bilbao, Spain, 7Guy’s and St’ Thomas NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, 8Guy’s and St’ Thomas NHS Foundation Trust, Dept. of Medical Oncology, London, United Kingdom, 9The Francis Crick Institute, Advanced Sequencing Facility, London, United Kingdom, 10Royal Marsden Hospital NHS Foundation Trust, Dept. of Medicine, London, United Kingdom

218
Intermittent hypoxia increases tumor angiogenesis in a mouse model of kidney cancer

By: Vilaseca Cabo A.1, Musquera M.1, Torres M.2, Campillo N.2, Gozal D.3, Montserrat J.4, Touijer K.5, Farré R.2, Almendros I.2, Alcaraz A.1

Institutes: 1Hospital Clínic De Barcelona, Dept. of Urology, Barcelona, Spain, 2Universitat De Barcelona, Dept. of Biophisics and Bioengineering, Barcelona, Spain, 3University of Chicago, Dept. of Sleep Disorders, Chicago, United States of America, 4Hospital Clínic De Barcelona, Dept. of Pneumology, Barcelona, Spain, 5Memorial Sloan-Kettering Cancer Center, Dept. of Urology, New York, United States of America

219
Quantification, culture and characterization of circulating endothelial progenitor cells in patients with renal cell carcinoma

By: Yang B., Gu W, Sun W., Guo C., Yao X., Zheng J.

Institutes: Shanghai Tenth People’s Hospital, Tongji University School Of Medicine, Dept. of Urology, Shanghai, China

220
Tumour-derived vascular endothelial growth factor mobilizes circulating endothelial progenitor cells and contributes to vasculogenesis of renal cell carcinoma

By: Yang B., Gu W., Guo C., Sun W., Che J., Liu M., Yao X., Zheng J.

Institutes: Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Dept. of Urology, Shanghai, China

221
Multi-region whole exome sequencing reveals monoclonal nature of inferior vena cava tumour thrombus extension in clear cell renal cell carcinoma

By: Stares M.1, Nicol D.2, O’Brien T.3, Challacombe B.3, Rowan A.1, Horswell S.4, Salm M.4, Soultati A.5, Hazell S.6, Chandra A.7, López J.8, Fisher R.9, Chowdhury S.5, Rudman S.5, Gore M.9, Larkin J.9, Matthews N.10, Turajlic S.1, Swanton C.1

Institutes: 1The Francis Crick Institute, Translational Cancer Therapeutics Laboratory, London, United Kingdom, 2Royal Marsden Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 3Guy’s and St Thomas’ NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 4The Francis Crick Institute, Dept. of Bioinformatics and Biostatistics, London, United Kingdom, 5Guy’s and St Thomas’ NHS Foundation Trust, Dept. of Medicine, London, United Kingdom, 6Royal Marsden Hospital NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, 7Guy’s and St Thomas’ NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, 8Cruces University Hospital, Dept. of Pathology, Bilbao, Spain, 9Royal Marsden Hospital NHS Foundation Trust, Dept. of Medicine, London, United Kingdom, 10The Francis Crick Institute, Advanced Sequencing Facility, London, United Kingdom

222
Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells is associated with poor prognosis in clear cell renal cell carcinoma

By: Füssel S.1, Toma M.2, Erdmann K.1, Wehner R.3, Kloß A.3, Baretton G.2, Wirth M.P.1, Schmitz M.3

Institutes: 1Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dept. of Urology, Dresden, Germany, 2Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dept. of Pathology, Dresden, Germany, 3Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dept. of Immunology, Dresden, Germany

223
Identification and validation of soluble carrier family expression signature for predicting poor outcome of renal cell carcinoma

By: Wan F., Ma C., Zhang H., Shi G., Zhu Y., Ye D.

Institutes: Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

224
Genetic alterations in specific chromosomal regions indicate metastatic potential in ccRCC patients

By: Grimm J.1, Janssen M.1, Hartmann A.2, Kunath F.3, Stöhr C.2, Stöckle M.1, Junker K.1

Institutes: 1UKS Universitätsklinikum des Saarlandes, Dept. of Urology and Pediatric Urology, Homburg/Saar, Germany, 2University Hospital Erlangen, Dept. of Pathology, Erlangen, Germany, 3University Hospital Erlangen, Dept. of Urology, Erlangen, Germany

225
Identification and validation of an 8-gene expression signature for predicting high Fuhrman grade renal cell carcinoma

By: Wan F.1, Zhu Y.2, Han C.2, Xu Q.3, Zhang H.2, Shi G.2, Gu W.2, Ye D.2

Institutes: 1Shanghai Medical College, Fudan University, Dept. of Oncology, Shanghai, China, 2Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, 3Fudan University Shanghai Cancer Center, Dept. of Pathology, Shanghai, China

226
Myopodin methylation correlates to tumour progression and predicts antiangiogenic response in kidney cancer

By: Perez-Lonzac A.2, Pompas-Veganzones N.2, Beltran M3, Beardo P.4, Vazquez F.5, Cozar J.M.5, Alvarez-Ossorio J.L.6, Sanchez-Carbayo M.1

Institutes: 1University of the Basque Country, Bladder Cancer Group, Vitoria-Gasteiz, Spain, 2University of the Basque Country, Translational Oncology Lab, Vitoria-Gasteiz, Spain, 3Hospital Puerta Del Mar, Dept. of Pathology, Cadiz, Spain, 4Hospital De Jerez, Dept. of Urology, Cadiz, Spain, 5Hospital Virgen De Las Nieves, Dept. of Urology, Cadiz, Spain, 6Hospital Puerta Del Mar, Dept. of Urology, Cadiz, Spain

227
Circulating free genomic and mitochondrial DNA fragments and their diagnostic and prognostic potential in clear cell renal cell carcinoma patients

By: Ralla B.1, Hongbiao L.1, Jung M.1, Rabenhorst S.1, Kilic E.1, Budach N.2, Fendler A.1, Jung K.1, Busch J.1

Institutes: 1Charité – Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, 2Charité – Universitätsmedizin Berlin, Dept. of Radiology, Berlin, Germany

228
Predictive molecular biomarkers of renal clear cell carcinoma

By: Trevisani F.1, Cascione L.2, Ghidini M.3, Lampis A.4, Fassan M.5, Hanhe J.K.4, Dell’Antonia G.6, Rigotti P.7, Larcher A.1, Capitanio U.1, Benigni F.1, Briganti A.1, Bertini R.1, Salonia A.1, Montorsi F.1, Valeri N.4

Institutes: 1IRCCS Ospedale San Raffaele, Dept. of Oncology, Department of Urology, URI, Milan, Italy, 2IOR – Institute of Oncology Research, Lymphoma and Genomics Research Program Bioinformatics Core Unit, Bellinzona, Switzerland, 3Hospital of Cremona, Dept. of Oncology, Cremona, Italy, 4Institute of Cancer Research, Laboratory of Gastrointestinal Cancer Biology and Genomics, London, United Kingdom, 5University of Padua, Dept. of Pathology, Padua, Italy, 6IRCCS Ospedale San Raffaele, Division of Pathology, Milan, Italy, 7University of Padua, Dept. of Surgical Science, Milan, Italy

229
Significance of TERT variants in renal cell carcinoma

By: Casuscelli J.1, Manley B.1, Redzematovic A.1, Becerra M.1, Tennenbaum D.1, Arcila M.1, Voss M.2, Feldman D.2, Motzer R.2, Coleman J.3, Russo P.3, Hsieh J.1, Hakimi A.A.3

Institutes: 1Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York City, United States of America, 2Memorial Sloan Kettering Cancer Center, Dept. of Medicine, New York City, United States of America, 3Memorial Sloan Kettering Cancer Center, Dept. of Surgery, New York City, United States of America

230
Blood based exosomal miRNAs as biomarkers for diagnosis and prognosis of clear cell renal cell cancer

By: Heinzelmann J.1, Baumgart S.2, Hoelters S.2, Janssen M.2, Stöckle M.2, Junker K.2

Institutes: 1Saarland University Medical Center, Dept. of Urology and Pediatric Urology, Hamburg, Germany, 2Saarland University Medical Center, Dept. of Urology and Pediatric Urology, Homburg, Germany